Treatment-Resistant Schizophrenia, Clozapine Resistance, Genetic Associations, and Implications for Precision Psychiatry: A Scoping Review
Genes · 10.03.2023 · 14 (3) · 689
DOI: 10.3390/genes14030689 ↗Kurz gefasst
Scoping Review in der Zeitschrift Genes, online erschienen am 10.03.2023. Verfasst von Jiangbo Ying und 3 weiteren Autor:innen. Beteiligte Einrichtung: East Region, Institute of Mental Health, Singapore 539747, Singapore. Hauptthemen laut MEDLINE: Clozapine, Schizophrenia, Antipsychotic Agents, Psychiatry. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 186 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Treatment-resistant schizophrenia (TRS) is often associated with severe burden of disease, poor quality of life and functional impairment. Clozapine is the gold standard for the treatment of TRS, although it is also known to cause significant side effects in some patients. In view of the burgeoning interest in the role of genetic factors in precision psychiatry, we conducted a scoping review to narratively summarize the current genetic factors associated with TRS, clozapine resistance and side effects to clozapine treatment. We searched PubMed from inception to December 2022 and included 104 relevant studies in this review. Extant evidence comprised associations between TRS and clozapine resistance with genetic factors related to mainly dopaminergic and serotoninergic neurotransmitter systems, specifically, TRS and rs4680, rs4818 within COMT, and rs1799978 within DRD2; clozapine resistance and DRD3 polymorphisms, CYP1A2 polymorphisms; weight gain with LEP and SNAP-25 genes; and agranulocytosis risk with HLA-related polymorphisms. Future studies, including replication in larger multi-site samples, are still needed to elucidate putative risk genes and the interactions between different genes and their correlations with relevant clinical factors such as psychopathology, psychosocial functioning, cognition and progressive changes with treatment over time in TRS and clozapine resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- East Region, Institute of Mental Health, Singapore 539747, Singapore.
- Research Division, Institute of Mental Health, Singapore 539747, Singapore.
- Department of PsychiSatry, University of Toronto, Toronto, ON M5R 0A3, Canada.
- Brain and Cognition Discovery Foundation Toronto, Toronto, ON M4W 3W4, Canada.
- West Region, Institute of Mental Health, Singapore 539747, Singapore.
ORCID-Profile: Jiangbo Ying, Qian Hui Chew, Kang Sim
Zitieren
APA
Ying, J., Chew, Q. H., McIntyre, R. S., & Sim, K. (2023). Treatment-Resistant Schizophrenia, Clozapine Resistance, Genetic Associations, and Implications for Precision Psychiatry: A Scoping Review. Genes, 14(3), 689. https://doi.org/10.3390/genes14030689
Vancouver
Ying J, Chew QH, McIntyre RS, Sim K. Treatment-Resistant Schizophrenia, Clozapine Resistance, Genetic Associations, and Implications for Precision Psychiatry: A Scoping Review. Genes. 2023;14(3):689. doi:10.3390/genes14030689
BibTeX
@article{Ying2023,
author = {Ying, Jiangbo and Chew, Qian Hui and McIntyre, Roger S and Sim, Kang},
title = {Treatment-Resistant Schizophrenia, Clozapine Resistance, Genetic Associations, and Implications for Precision Psychiatry: A Scoping Review},
journal = {Genes},
year = {2023},
volume = {14},
number = {3},
pages = {689},
doi = {10.3390/genes14030689}
}
EUVIMED